Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics reports developments as a clinical-stage biopharmaceutical company focused on antibody-drug conjugates for cancers with high unmet medical need. Its news centers on the company’s Dolasynthen and Immunosynthen ADC platforms, including Emi-Le, or emiltatug ledadotin; XMT-1660, a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a HER2 epitope.
Recurring updates include clinical data and trial disclosures for solid-tumor programs, business and financial results, material agreements, shareholder voting matters, governance items, capital-structure actions, and Nasdaq listing-related disclosures.
Summary not available.
Mersana Therapeutics (NASDAQ:MRSN) announced today that its management team will hold a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 2:40 p.m. ET. A live webcast will be accessible through the Investors & Media section of Mersana’s website, with an archived replay available for 90 days post-event. The company focuses on developing antibody-drug conjugates (ADCs) aimed at addressing high unmet medical needs in cancer treatment, including lead candidate upifitamab rilsodotin targeting platinum-resistant ovarian cancer.
Mersana Therapeutics (NASDAQ:MRSN), a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced that CEO Anna Protopapas will present a company overview at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 3:20 p.m. ET. Investors can access a live webcast on Mersana's website, with an archived replay available for 90 days post-event. Mersana is developing innovative ADCs to improve cancer treatment, with its lead candidate, upifitamab rilsodotin (UpRi), targeting platinum-resistant ovarian cancer.
Mersana Therapeutics (NASDAQ:MRSN) reported significant advancements in its clinical pipeline, particularly regarding UpRi, a treatment for ovarian cancer. Updated data showed a confirmed objective response rate (ORR) of 34% in patients with NaPi2b high ovarian cancer, supporting the ongoing UPLIFT study. The company introduced UP-NEXT, a Phase 3 study for UpRi maintenance therapy in platinum-sensitive patients. Financially, Mersana ended Q3 2021 with about $192 million in cash and new credit access of $100 million, bolstering its operational capabilities.
Mersana Therapeutics (NASDAQ:MRSN) announced a conference call on November 9, 2021, at 8:00 a.m. ET to discuss third-quarter financial results ending September 30, 2021. The clinical-stage biopharmaceutical company specializes in antibody-drug conjugates (ADCs) for cancer treatment and is developing several product candidates, including upifitamab rilsodotin (UpRi). UpRi targets NaPi2b and is under evaluation in multiple studies for ovarian cancer treatment. Investors can access the call via phone or webcast through the company’s website.
Mersana Therapeutics (Nasdaq: MRSN) has appointed Mohan Bala, Ph.D., as Senior Vice President of Strategic Product Planning & Program Leadership. To entice Dr. Bala, the Compensation Committee granted him a stock option for 112,500 shares at $8.63 per share, the closing price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary of his start date and the remainder vesting quarterly. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer treatment, including their lead candidate UpRi for ovarian cancer.
Mersana Therapeutics has appointed Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective October 25, 2021. He takes over responsibilities from Brian DeSchuytner, who has been named SVP and Chief Financial Officer. Dr. Bala brings over 20 years of experience in clinical development, having launched seven oncology products globally. This leadership change is expected to strengthen Mersana's efforts in advancing its clinical pipeline, especially UpRi, a candidate for treating ovarian cancer.
Mersana Therapeutics (NASDAQ:MRSN) has announced promising preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targeting a novel epitope of HER2. Presented at the AACR-NCI-EORTC conference, data shows that XMT-2056 activates the STING pathway effectively in tumor cells and immune cells, outperforming trastuzumab-TLR7/8 agonist ADCs. The ADC demonstrates increased efficacy in various HER2 models and potential for combination treatments with existing HER2 therapies. The compound also shows excellent tolerability in NHP studies, suggesting a broad therapeutic index.
Mersana Therapeutics (NASDAQ:MRSN) announced its upcoming presentation of preclinical data for XMT-2056, its first STING-agonist ADC, at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics. The session is scheduled for October 7, 2021, featuring Dr. Timothy B. Lowinger, the Chief Science & Technology Officer. This event highlights Mersana's innovations in antibody-drug conjugates aimed at targeting cancers with significant unmet medical needs, strengthening its pipeline that includes UpRi and XMT-1592.
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, announced management presentations at three investor conferences. The Baird 2021 Global Healthcare Conference will take place on September 14, 2021, at 8:30 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. Lastly, the 2021 Cantor Virtual Global Healthcare Conference is set for September 28, 2021, at 4:00 p.m. ET. A live webcast will be accessible on Mersana's website, with an archived replay available for 90 days.